Clinical Trial Update: TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study [Phase 1]

View source ↗

Summary

Phase 1 trial update for TMC435-TiDP16-C116 assessing relative bioavailability and the effect of food in Hepatitis C patients; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED